Literature DB >> 16678164

Heat shock proteins reduce alpha-synuclein aggregation induced by MPP+ in SK-N-SH cells.

Guo-Hua Fan1, Hai-Yan Zhou, Hui Yang, Sheng-Di Chen.   

Abstract

Alpha-synuclein has been implicated in the pathogenesis of Parkinson's disease (PD). Heat shock proteins (HSPs) can reduce protein misfolding and accelerate the degradation of misfolded proteins. 1-methyl-4-phenylpyridinium ion (MPP+) is the compound responsible for the PD-like neurodegeneration caused by MPTP. In this study, we found that MPP+ could increase the expression of alpha-synuclein mRNA but could not elevate proteasome activity sufficiently, leading to alpha-synuclein protein accumulation followed by aggregation. Both HSPs and HDJ-1, a homologue of human Hsp40, can inhibit MPP+-induced alpha-synuclein mRNA expression, promote ubiquitination and elevate proteasome activity. These findings suggest that HSPs may inhibit the MPP+-induced alpha-synuclein expression, accelerate alpha-synuclein degradation, thereby reducing the amount of alpha-synuclein protein and accordingly preventing its aggregation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16678164     DOI: 10.1016/j.febslet.2006.04.057

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

Review 1.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 2.  Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance.

Authors:  R Anne Stetler; Rehana K Leak; Yu Gan; Peiying Li; Feng Zhang; Xiaoming Hu; Zheng Jing; Jun Chen; Michael J Zigmond; Yanqin Gao
Journal:  Prog Neurobiol       Date:  2014-01-02       Impact factor: 11.685

Review 3.  Targeting heat shock proteins to modulate α-synuclein toxicity.

Authors:  Daryl Rhys Jones; Simon Moussaud; Pamela McLean
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

Review 4.  Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases.

Authors:  William B Pratt; Jason E Gestwicki; Yoichi Osawa; Andrew P Lieberman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-09-25       Impact factor: 13.820

5.  Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation.

Authors:  Tiago Fleming Outeiro; Jochen Klucken; Katherine E Strathearn; Fang Liu; Paul Nguyen; Jean-Christophe Rochet; Bradley T Hyman; Pamela J McLean
Journal:  Biochem Biophys Res Commun       Date:  2006-10-26       Impact factor: 3.575

6.  Dominant-positive HSF1 decreases alpha-synuclein level and alpha-synuclein-induced toxicity.

Authors:  Xu Liangliang; Hou Yonghui; E Shunmei; Gong Shoufang; Zhou Wei; Zou Jiangying
Journal:  Mol Biol Rep       Date:  2009-07-17       Impact factor: 2.316

7.  Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells.

Authors:  Ashley D Reynolds; David K Stone; R Lee Mosley; Howard E Gendelman
Journal:  J Proteome Res       Date:  2009-07       Impact factor: 4.466

Review 8.  Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.

Authors:  Darius Ebrahimi-Fakhari; Laiq-Jan Saidi; Lara Wahlster
Journal:  Acta Neuropathol Commun       Date:  2013-12-05       Impact factor: 7.801

Review 9.  Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments.

Authors:  Panchanan Maiti; Jayeeta Manna; Gary L Dunbar
Journal:  Transl Neurodegener       Date:  2017-10-25       Impact factor: 8.014

Review 10.  The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology.

Authors:  Destiny-Love Manecka; Benoît Vanderperre; Edward A Fon; Thomas M Durcan
Journal:  Front Mol Neurosci       Date:  2017-09-27       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.